VANCOUVER, British Columbia, September 28, 2020 — AbCellera today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Every year Fierce Biotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers, and a competitive market position.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases, and other disorders still need treatment, Fierce Biotech Senior Editor Ben Adams said. “This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology,” said Adams.
AbCellera’s full-stack, AI-powered technology sources, searches, decodes and analyzes natural immune responses to identify antibodies for next-generation therapeutics. Over the past two years, under DARPA’s Pandemic Prevention Platform (P3) program, the company tailored its technology for rapid pandemic response, which contributed to the world’s first COVID-19 clinical trial for a potential monoclonal antibody treatment.
LY-CoV555 is a neutralizing antibody against SARS-CoV-2 that emerged from AbCellera’s collaboration with Eli Lilly and was discovered in collaboration with AbCellera and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. Starting from a single blood sample obtained from a convalescent patient, LY-CoV555 was identified within three weeks and it was advanced into clinical testing in 90 days and is currently in Phase 3 clinical trials.
“Our response to COVID-19 is a time-compressed example of why AbCellera exists – to build and bring together the teams and technologies needed to solve the toughest problems in drug development,” said Carl Hansen, Ph.D., CEO of AbCellera. “Drug development takes too long, fails too often, and costs too much. To solve this, we’re building a modern operating system for drug developers to ensure the best science is translated quickly into new therapies for patients.”
AbCellera’s antibody discovery platform integrates patented and proprietary technologies to advance the development of new biological modalities, from monoclonal, multi-specific, and single-domain antibodies, to bioconjugates, gene-encoded biologics, and cell therapies. For the company’s partners, AbCellera has successfully completed more than 55 programs, delivering high-quality antibody drug candidates for a wide variety of drug targets, including historically challenging multi-pass membrane protein targets, such as GPCRs and ion channels. The company has generated lead therapeutic antibody candidates for unmet needs in various disease areas including cancer, immuno-oncology, neurodegeneration, pain, fibrosis, and metabolic disorders.
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About AbCellera Biologics Inc.
AbCellera is a privately held technology company with an antibody discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new antibody drug candidates and aims to reduce the time it takes to bring treatments to the clinic. AbCellera’s partners include leading biotechnology companies, global health organizations, and top 10 biopharmaceutical companies. For more information, visit abcellera.com.
Jessica Yingling; email@example.com, +1.236.521.6774 (AbCellera Media)
Kevin Heyries; firstname.lastname@example.org, +1.604.559.9005 (AbCellera Business Development)